Vical, Inc. is a biopharmaceutical company. The company engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Its core technology involves the insertion of DNA into plasmids designed to deliver the desired genes into cells in the body. The company&#x27;s pipeline consists of ASP0113 Therapeutic CMV Vaccine, CyMVectin Prophylactic CMV Vaccine and VL-2397 Antifungal. Vical was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA.
